Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
- PMID: 16170322
- DOI: 10.1038/nm1297
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
Abstract
Antigen-specific T cells circulate freely and accumulate specifically at sites of antigen expression. To enhance the survival and targeting of systemically delivered viral vectors, we exploited the observation that retroviral particles adhere nonspecifically, or 'hitchhike,' to the surface of T cells. Adoptive transfer of antigen-specific T cells, loaded with viruses encoding interleukin (IL)-12 or Herpes Simplex Virus thymidine kinase (HSVtk), cured established metastatic disease where adoptive T-cell transfer alone was not effective. Productive hand off correlated with local heparanase expression either from malignant tumor cells and/or as a result of T-cell activation by antigen, providing high levels of selectivity for viral transfer to metastatic tumors in vivo. Protection, concentration and targeting of viruses by adsorption to cell carriers represent a new technique for systemic delivery of vectors, in fully immunocompetent hosts, for a variety of diseases in which delivery of genes may be therapeutically beneficial.
Comment in
-
Hitchhiker's guide to the T cell.Nat Med. 2005 Oct;11(10):1051-2. doi: 10.1038/nm1005-1051. Nat Med. 2005. PMID: 16211037 No abstract available.
Similar articles
-
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.Cancer Res. 2003 Jun 15;63(12):3173-80. Cancer Res. 2003. PMID: 12810645
-
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.Gene Ther. 2006 Aug;13(15):1166-77. doi: 10.1038/sj.gt.3302722. Epub 2006 Apr 20. Gene Ther. 2006. PMID: 16625245
-
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.Gene Ther. 2007 Jul;14(13):998-1009. doi: 10.1038/sj.gt.3302935. Epub 2007 Apr 19. Gene Ther. 2007. PMID: 17443216
-
Viral vectors for gene transfer into antigen presenting cells.Curr Opin Mol Ther. 1999 Oct;1(5):558-64. Curr Opin Mol Ther. 1999. PMID: 11249662 Review.
-
[Gene therapy and cancer: from concepts to clinical applications].Pathol Biol (Paris). 1993 Oct;41(8):686-90. Pathol Biol (Paris). 1993. PMID: 8290313 Review. French.
Cited by
-
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.Cells. 2021 Apr 22;10(5):978. doi: 10.3390/cells10050978. Cells. 2021. PMID: 33922052 Free PMC article.
-
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.Theranostics. 2015 Jun 8;5(9):1007-20. doi: 10.7150/thno.11742. eCollection 2015. Theranostics. 2015. PMID: 26155316 Free PMC article. Review.
-
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.Oncolytic Virother. 2015 Jun 18;4:75-82. doi: 10.2147/OV.S54738. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512672 Free PMC article. Review.
-
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020. Front Immunol. 2020. PMID: 32411132 Free PMC article. Review.
-
Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.J Control Release. 2014 Sep 28;190:531-41. doi: 10.1016/j.jconrel.2014.03.050. Epub 2014 Apr 18. J Control Release. 2014. PMID: 24747161 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical